| Execution period | Financial Year ended March 31, 2026 |
|---|
BSE filing, NSE: ANUHPHR. Summary written from the filing by ALFA Finder's alert engine.
Anuh Pharma Ltd: key numbers
- Share price
- ₹79.90
- Market cap
- ₹800.8 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 18.1×Sector 46.1×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Board Meeting Date
Anuh Pharma's board meets on 30 October 2026 to approve Q1/H1 FY27 results. Trading window closed for insiders until 1 November 2026.
Anuh Pharma Acquisition Worth ₹72.9 Cr
Anuh Pharma signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma for ₹72.90 Crore, increasing its production capacity by 525 MTPA.
- Value
- ₹72.90 Cr
- manufacturing capacity
- 525.0 MTPA
Anuh Pharma Debt & Borrowing: ₹75 Cr
Anuh Pharma Ltd board approved a loan of ₹75 Crore to finance manufacturing asset investments for expanding production capacity.
- Value
- ₹75.00 Cr
Anuh Pharma Other Announcement
Anuh Pharma Ltd filed the quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as issued by its RTA.
Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Investor Presentation: Key Takeaways
Anuh Pharma reported strong Q1 FY27 results with 4% YoY revenue growth and 38% PAT growth, driven by a shift to high-value regulated markets.
- Call
- Guides 18% growth
Other other announcement announcements
All →HEG Advanced Materials Other Announcement
HEG Advanced Materials Limited has intimated the exchange regarding the change of its Corporate Identification Number (CIN) following an approved scheme of arrangement.
Sanofi India Other Announcement
Sanofi India issued a communication regarding Tax Deduction at Source (TDS) for the interim dividend declared for FY 2026. Shareholders must update details by November 5, 2026.
Visaka Industries Other Announcement
Visaka Industries informed the exchange about sending reminder letters to shareholders regarding the compulsory transfer of unclaimed dividends and equity shares to the IEPF account.
Arvaya Healthcare Other Announcement
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
AYM Syntex Other Announcement
AYM Syntex's board appointed BSR & Co. LLP as statutory auditor for five years, subject to shareholder approval. Routine auditor appointment; no monetary value involved.
- Execution
- Five consecutive years, from the conclusion of the 44th AGM to the conclusion of the 49th AGM
Kalpataru Other Announcement
Kalpataru filed CARE Ratings' IPO monitoring report for the quarter ended September 30, 2026. It reports no deviation from offer objects, though fund co-mingling was noted.